Specialty firm adding reps for hot-flash gel
The reps will pitch Elestrin to OB/GYNs as part of Bradley’s Kenwood Therapeutics division, which received FDA approval for the product last December.
The company estimates the size of the
Bradley in-licensed Elestrin from BioSante Pharmaceuticals late
last year and has the exclusive
The small specialty firm says Elestrin fits into its strategic plan to in-license Phase II and Phase III drugs with long- term intellectual property protection and bring them to market. Elestrin’s patent protects it until 2022.